Key Segments:
By Modality
-
Research
-
Commercialized
By Therapy Type
-
CAR T-Cell Therapy
-
TCR-Based Therapy
-
Tumor-Infiltrating Lymphocyte Therapy
By Indication
-
Hematologic Malignancies
-
Solid Tumors
-
Others
By End User
-
Hospitals & Cancer Treatment Centers
-
Specialty Cancer Clinics
-
Academic & Research Institutes
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Novartis, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Iovance Biotherapeutics, Autolus Therapeutics and Adaptimmune Therapeutics, among others. These companies compete on approved product breadth, manufacturing capacity and solid tumor pipeline depth.
The main opportunities lie in allogeneic and in vivo platforms that could remove manufacturing wait times, expansion into solid tumor indications and consolidation activity that brings new cell therapy programs under larger, better-resourced sponsors.
The key growth factor is the combination of expanding regulatory approvals across therapy types and growing manufacturing capacity, which together are widening the pool of patients who can access cell therapy sooner in their treatment course.
By therapy type, the CAR T-Cell Therapy segment dominated the market with approximately 74.60% share in 2025, supported by the longest approval history and the broadest set of marketed products.
North America dominated the market with approximately 46.75% share in 2025, supported by its accredited treatment center network and established reimbursement pathways. Asia Pacific is the fastest-growing region with a projected CAGR of 37.85% from 2026 to 2035.
